Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Phase 1
Terminated
- Conditions
- T-Cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: CD5 CART
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05032599
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Phase 1
Terminated
- Conditions
- T Cell LymphomaT-cell Leukemia
- Interventions
- Drug: Efficacy of LCAR-T2C CAR-T cells
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT04973527
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Phase 1
Completed
- Conditions
- T Cell LymphomaT-cell Leukemia
- Interventions
- Biological: chimeric antigen receptor T cell treatment
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT04840875
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Refractory Acute Myeloid LeukemiaRelapse LeukemiaAcute Myeloid Leukemia
- Interventions
- Biological: chimeric antigen receptor T cell
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT04835519
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Phase 2
Completed
- Conditions
- Refractory T Lymphoblastic Leukemia/LymphomaRelapse/RecurrenceT-cell Leukemia/Lymphoma
- Interventions
- Biological: chimeric antigen receptor T cell treatment
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT04689659
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Study of Sequential CAR-T Cell Treating Leukemia Children
Phase 2
Terminated
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
- Interventions
- Biological: chimeric antigen receptor T cell
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT04340154
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
Phase 2
Completed
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- Biological: Autologous humanized anti-CD22 chimeric antigen receptor T cells
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT04340167
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Phase 2
Completed
- Conditions
- Refractory Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in Relapse
- Interventions
- Biological: Murine autologous anti-CD19 chimeric antigen receptor T cells
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT04325841
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath